Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

万凯锐 - NMPA Drug Approval Details

Approvals/NMPA/Cabotegravir Sodium Tablets

Approved

化学药品

Cabotegravir Sodium Tablets

ViiV Healthcare BV🇨🇳 National Medical Products Administration

Approval Date: Jul 11, 2023
Approval ID: 8TEML9aSTZE
Company: ViiV Healthcare BV
Type: 化学药品

Approval Details

Approval Id: 8TEML9aSTZE
Approval Number: 国药准字HJ20230094
Generic Name: 卡替拉韦钠片
Generic Name En: Cabotegravir Sodium Tablets
Trade Name: 万凯锐
Drug Type: 化学药品
Dosage Form: 片剂
Strength: 30mg（按C₁₉H₁₇F₂N₃O₅计）
Reg Date: 2023-07-11
Expired Date: 2028-07-10
Company Name: ViiV Healthcare BV
Company Detail Path: /organization/viiv-healthcare-bv

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Jul 11, 2023

Approval ID

8TEML9aSTZE

Type

化学药品

Back to NMPA Approvals